Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications bromelain treatment decreases secretion pro inflammatory cytokines chemokines colon
… Willingness-to-Pay Given your product’s treatment features, do you know how much your patient’s value … dosing regimen changes from 3 times a day to 1? Length of treatment decreases to 5 days instead of 10? The delivery mechanism …
… Advances in Inflammatory Bowel Diseases Share on: Thursday, December 14 … Solutions experts will be presented at the Advances in Inflammatory Bowel Diseases conference. Real-world experience and perspectives on the treatment of crohn's disease: results from a healthcare …
… PRO Analysis Portfolio Across Multiple Cancers OPPORTUNITY … estimate the average differences in HRQOL scores between treatment groups during follow-up while controlling for … to compare the risk of deterioration in HRQOL between treatment groups and to estimate the median time to …
… Webinar: Characteristics of Recent PRO Labeling by the FDA and EMA for Oncology Drugs Share on: … (EMA) and US Food and Drug Administration (FDA) for cancer treatment found that the agencies use different standards to … by study authors and based on PRO labeling of cancer treatment drugs, focuses on key differences between the 2 …
… RTI-HS Webinar - Lessons Learned From a Review of FDA PRO Labeling Share on: December 12, 2016 Image Click to view this webinar - Lessons Learned from a Review of FDA PRO Labeling The last decade has seen an increased focus on … Product labeling based on patient-reported outcomes (PRO) endpoints are therefore of special interest to drug …
FDA Rare Disease Day 2024 Virtual Public Meeting Share on: Friday, March 1, 2024, 9am - 4:30pm Meeting Agenda & Links We are pleased that Carla (DeMuro) Romano, M.S., Vice President of Patient-Centered Outcomes Assessment at RTI Health Solutions, will be …
… Research (HEOR) Strategy Plans and Gap Analyses for a Treatment Targeting Multiple Rare Diseases OPPORTUNITY Our … product in multiple phase 2 and 3 clinical trials for the treatment of numerous rare disease indications (chronic inflammatory demyelinating polyneuropathy (CIDP), pemphigus …
… Analysis of Heterogeneity of Treatment Effects for Patient-Centered Outcomes Let us help … for personalized medicine. Drug research focuses on treatment differences and disease differences—much to the … people for which it isn’t. This is called heterogeneity of treatment effects. More and more regulatory and …
… health-related outcome such as a health state event or treatment side-effect. Utility scores are used in health … Develop a health preference index from a disease-specific PRO instrument - Conduct health preference assessments using … such as NICE, SMC, CDR, and PBAC), value messaging , and publications A Team Approach Let our multidisciplinary team …
… within the last 6 months, or in patients with concomitant treatment with two or more additional antiplatelet agents …